XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August7, 2017, we announced our financial results for the quarter ended June30, 2017 in the press release attached hereto as Exhibit99.1 and incorporated herein by reference.

The information herein and in the exhibit hereto is being furnished and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release dated August7, 2017.


Xencor Inc Exhibit
EX-99.1 2 a17-18960_1ex99d1.htm EX-99.1 Exhibit 99.1   Xencor Reports Second Quarter 2017 Financial Results   — Management to Host Conference Call Today at 4:30 p.m. ET —   MONROVIA,…
To view the full exhibit click here

About XENCOR,INC. (NASDAQ:XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.